Discovery of New Classes of Therapeutic Agents

Research Team:  Hoffman, Huang, Meade, Nguyen, Scheidt, Silverman, Stupp, O'Halloran, Ouchi, Rosen, Woloschak

Several advances in the cancer therapeutics arena have emerged from this sub-group. Many of these discoveries arise from interdisciplinary interactions between experts in the fields of Synthetic Chemistry, Nanotechnology and Physiology. A good balance between clinician scientists and basic scientists is indicative of the strong translational character of this group. Drug discovery projects include the synthesis of novel small molecules (Hoffman, Meade, Silverman), polymer nanoparticles (Nguyen, Scheidt, Stupp), modified liposome systems (Nguyen, O'Halloran), and bioinorganic assemblies of established anticancer drugs (Hoffman, O'Halloran, Rosen, Scheidt, Silverman, Stupp and Woloschak), as well as gene therapy (Dean) and chemopreventative agents (Yang). Several teams have developed novel target-based assays and are screening small molecules for anticancer activity (Huang, Ouchi), while others are working on multifunctional agents that can be monitored in situ and deliver anticancer drug cargo (Meade, Nguyen, O'Halloran, Stupp). One of the strengths of this Program is the connectivity between the understanding the fundamental mechanisms that control growth and differentiation with innovative diagnostic and therapeutic agents.

Previous Page